Mobility Management

  • Home
  • Topics
    • Automotive Mobility
    • Billing / Reimbursement
    • Government / Legislation
    • Home Accessibility
    • Pediatrics
    • Power Chairs
    • Seating & Positioning
    • Ultralightweights
  • News
  • Featured
  • Podcasts
  • Request Media Kit
  • Webinars
  • Subscribe
  • Digital Edition
  • Awards
  • Advertise

Anti-Inflammatory Drug Delayed ALS Onset in Mice: Study

December 5, 2019 by Laurie Watanabe

An anti-inflammatory drug currently approved by the U.S. Food & Drug Administration to treat conditions such as ulcerative colitis and asthma delayed the onset of amyotrophic lateral sclerosis (ALS) symptoms in mice, researchers say.

Cromolyn sodium prevented motor neuron degeneration in the mice and was “neuroprotective” by decreasing inflammation, leading researchers to suspect that inflammatory processes are significantly tied to ALS.

The study, “Cromolyn Sodium Delays Disease Onset and Is Neuroprotective in the SOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis,” was published in Scientific Reports in November.

In the study’s abstract, researchers said, “Accumulating evidence suggests that neuroinflammatory processes are implicated in the initiation and progression of amyotrophic lateral sclerosis.”

While neurological symptoms were delayed in all the mice that received the cromolyn sodium treatment, only female mice experienced improvement in survival rates.

“Furthermore, there was a significant increase in motor neuron survival in the lumbar spinal cord as well as a significant decrease in the denervation of the neuromuscular junction of the tibialis anterior muscle in cromolyn-treated transgenic SOD1G93A mice,” researchers said.

The 149 mice in the study, some of which had the genetic mutation that would cause ALS-like presentations, received cromolyn sodium injections once a day for five days a week. All the mice were subjected to various tests, such as the ability to fully extend their hind legs away from lateral midline when suspended by their tails. They were also observed for signs of minimal joint movement, paralysis, or the inability to stand when laid on their sides.

The mice that had been given cromolyn sodium treatments were slower to show signs of mobility impairment.

Related Articles Read More >

Briefly: Researchers Find a Cause for Familial ALS; ADA’s 35th Anniversary Upcoming
Featuring Okayama University and the ADA National Network.
Mobility Management Kicks Off 2025 Mobility Product Awards Program
Annual program honors innovative seating, wheeled mobility, and accessibility technology.
Proposed Rule in Depth: CMS Scrutinizes Accrediting Organizations, DMEPOS Suppliers
The Centers for Medicare & Medicaid Services wants suppliers to be reaccredited annually.
Briefly: Miller’s Returns to Top Workplaces List; Adaptive Imports Announces Code for Headaloft
Featuring Miller’s Rental and Sales, Cleveland Plain Dealer, and Adaptive Imports.

GET THE FREE NEWSLETTER

Mobility Management Newsletter

Subscribe to Mobility Management's newsletter for industry & product news, trends and resources. Click here.
podcasts
Mobility Management
  • HME Business
  • Senior Housing News
  • Home Health Care News
  • Skilled Nursing News
  • Hospice News
  • Behavioral Health Business
  • Contact Us
  • About Us

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Mobility Management

  • Home
  • Topics
    • Automotive Mobility
    • Billing / Reimbursement
    • Government / Legislation
    • Home Accessibility
    • Pediatrics
    • Power Chairs
    • Seating & Positioning
    • Ultralightweights
  • News
  • Featured
  • Podcasts
  • Request Media Kit
  • Webinars
  • Subscribe
  • Digital Edition
  • Awards
  • Advertise